What this test measures
- Non-HDL CholesterolDerived biomarker
Total cholesterol less HDL, leaving every particle thought to drive plaque.
Non-HDL cholesterol is your total cholesterol minus your HDL cholesterol. What is left is the cholesterol carried by the particles that can help build plaque in artery walls: LDL, VLDL, IDL and lipoprotein(a). It needs no extra blood, works on a non-fasting sample, and guidelines in the UK, Europe and the US now use it alongside LDL cholesterol.
What non-HDL cholesterol measures
Total cholesterol counts the cholesterol on every lipoprotein particle in the blood. HDL particles carry cholesterol back to the liver. Take HDL away and the remainder sits on the ApoB-carrying particles, so non-HDL cholesterol is often used as a stand-in for ApoB, although the two can part ways when triglycerides are high.
It has two practical strengths. A standard LDL figure is often calculated with a formula that becomes unreliable when triglycerides are high, and some labs do not report it at all once triglycerides pass 4.5 mmol/L, while non-HDL is simply one measured value minus another. And eating barely moves it: after an ordinary meal it falls by at most about 0.2 mmol/L (8 mg/dL), which a joint European consensus judged clinically insignificant.
Non-HDL cholesterol normal range
Non-HDL cholesterol is given in mmol/L or mg/dL; to convert, multiply mmol/L by 38.6. What counts as healthy depends on a person's overall cardiovascular risk, so the figures below are reference points rather than one normal range:
| Non-HDL cholesterol | mmol/L | mg/dL | Source |
|---|---|---|---|
| Healthy level for adults | below 4.0 | below about 155 | NHS |
| Flagged on lab reports (non-fasting sample) | 3.9 or above | 150 or above | EAS and EFLM joint consensus |
| Goal for a healthy lipid profile, or at borderline to moderate risk | below 3.4 | below 130 | NHLBI; ESC/EAS 2019; ACC/AHA 2026 |
| Goal at high risk | below 2.6 | below 100 | ESC/EAS 2019; ACC/AHA 2026 |
| Goal at very high risk | below 2.2 | below 85 | ESC/EAS 2019 |
| Specialist assessment advised | above 7.5 | above about 290 | NICE |
Europe's SCORE2 risk charts now use non-HDL cholesterol in place of total cholesterol. Ranges vary by laboratory, method, age and sex, so read your result against the range on your own report.
What a high non-HDL usually points to
A high non-HDL cholesterol means more cholesterol on the particles that can lodge in artery walls. It usually reflects a raised LDL, raised triglycerides, or both, and sometimes an inherited lipid disorder. It is a risk marker, not a diagnosis.
A doctor will usually look at the parts that make it up, total cholesterol and HDL, alongside LDL, triglycerides and ApoB, and then at overall risk. Before referring anyone to a specialist, NICE advises ruling out common secondary causes such as an underactive thyroid, uncontrolled diabetes, liver disease, nephrotic syndrome and heavy drinking, which is why TSH, HbA1c and liver and kidney tests often sit beside it.
What a low non-HDL usually points to
A low non-HDL cholesterol is the direction guidelines aim for. On cholesterol-lowering treatment, it is one of the numbers used to judge the response: NICE uses the change in non-HDL cholesterol to check how well treatment is working.
What moves non-HDL cholesterol
- Anything that moves its parts. It rises when total cholesterol rises or HDL falls, so weight, diet, smoking and activity all reach it through those two values.
- Meals. A recent meal lowers it by about 0.2 mmol/L at most, too little to matter clinically.
- Pregnancy. Total cholesterol rises by about 43% by the third trimester and HDL by about 25% in one cohort, so non-HDL rises too, then settles after delivery.
- Other conditions. An underactive thyroid, uncontrolled diabetes, liver disease and nephrotic syndrome can all raise lipids.
- Two measurements. Because it is calculated, any error in total cholesterol or HDL carries straight into non-HDL.
Preparing for the test
Non-HDL cholesterol does not need fasting: NICE does not require a fasting sample for a full lipid profile. If a non-fasting triglyceride result is above 5 mmol/L, the European consensus suggests a doctor may repeat the profile fasting. In a panel that includes fasting glucose and fasting insulin, the sample is taken after a fast anyway. Water is allowed.
How Clare's panel handles non-HDL cholesterol
In Clare's panel, non-HDL cholesterol is calculated by Clare from two lab results, total cholesterol and HDL cholesterol, by subtracting one from the other:
Non-HDL cholesterol = Total Cholesterol minus HDL Cholesterol
For example, a total cholesterol of 5.2 mmol/L with an HDL of 1.3 mmol/L gives a non-HDL cholesterol of 3.9 mmol/L. Both inputs come from the same sample, so the figure reflects the same moment.
Why it matters in the UAE
We found no UAE study that reports non-HDL cholesterol itself. The nearest data come from a household survey of 824 Emirati adults in the Northern Emirates, with fasting samples taken in 2012 and 2013: 42.8% had a total cholesterol of 5.2 mmol/L or more, and 29% had triglycerides of 1.7 mmol/L or more. Raised triglycerides are the setting in which guidelines lean on non-HDL cholesterol and ApoB rather than calculated LDL.
Related tests
Non-HDL cholesterol is built from Total Cholesterol and HDL Cholesterol, and is usually read with Apolipoprotein B (ApoB) and Remnant Cholesterol. For why particle counts can tell a different story from cholesterol, read ApoB: the cholesterol number most UAE panels skip.
Why non-HDL cholesterol means more over time
Lipid tests are usually repeated every five years when results are normal, and more often with diabetes, high blood pressure or heart disease, or on cholesterol-lowering treatment. Non-HDL cholesterol suits that kind of tracking because a meal barely moves it. A later result set against an earlier one shows whether a change in weight, diet or treatment moved the cholesterol that matters for arteries, and by how much. Clare is opening with a waitlist at clare.health.
- ESC/EAS, 2019 Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk, European Heart Journal (2020) https://academic.oup.com/eurheartj/article/41/1/111/5556353
- ESC/EAS, 2025 Focused Update of the 2019 Guidelines for the management of dyslipidaemias, European Heart Journal (2025) https://academic.oup.com/eurheartj/article/46/42/4359/8234482
- Nordestgaard et al., Fasting is not routinely required for determination of a lipid profile: joint consensus statement from the EAS and EFLM, European Heart Journal (2016) https://pmc.ncbi.nlm.nih.gov/articles/PMC4929379/
- NICE, NG238 Cardiovascular disease: risk assessment and reduction, including lipid modification (2023) https://www.nice.org.uk/guidance/ng238/chapter/Recommendations
- NHS, High cholesterol: cholesterol levels (reviewed 2026) https://www.nhs.uk/conditions/high-cholesterol/cholesterol-levels/
- National Heart, Lung, and Blood Institute (NIH), Blood cholesterol: diagnosis (2024) https://www.nhlbi.nih.gov/health/blood-cholesterol/diagnosis
- American College of Cardiology, Lower sooner: how the 2026 dyslipidemia guideline changes practice, Cardiology Magazine (2026) https://www.acc.org/latest-in-cardiology/articles/2026/07/01/01/prioritizing-health
- Millan et al., Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention, Vascular Health and Risk Management (2009) https://pmc.ncbi.nlm.nih.gov/articles/PMC2747394/
- Kronenberg et al., Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement, European Heart Journal (2022) https://pmc.ncbi.nlm.nih.gov/articles/PMC9639807/
- Wild and Feingold, Effect of pregnancy on lipid metabolism and lipoprotein levels, Endotext, NCBI Bookshelf (updated 2026) https://www.ncbi.nlm.nih.gov/books/NBK498654/
- MedlinePlus (US National Library of Medicine), Cholesterol testing and results (reviewed 2026) https://medlineplus.gov/ency/patientinstructions/000386.htm
- Mahmoud and Sulaiman, Dyslipidaemia prevalence and associated risk factors in the United Arab Emirates: a population-based study, BMJ Open (2019) https://pmc.ncbi.nlm.nih.gov/articles/PMC6858122/
Last updated